Picture [iito] Life Science Business Portals Media Data 2022 2 650x100px
Organisation › Details

Dunad Therapeutics Ltd.

Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted protein degradation therapies. Dunad's platform enables selective degradation via direct target modification using tuneable mono-valent small molecules, allowing for the development of more drug-like, orally bioavailable and CNS-accessible protein degraders. Dunad was founded in 2020 and is headquartered in Cambridge, UK with operations in both the UK and North America, and is backed by Epidarex Capital. *


Period Start 2020-08-14 renamed
Product Industry protein degradation technology
Region Region Cambridge, Cambridgeshire
  Country United Kingdom (GB)
  Street 30 Broad Street
Great Cambourne
  City CB23 6HJ Cambridge
    Address record changed: 2021-03-27
Basic data Employees n. a.
    * Document for �About Section�: Dunad Therapeutics. (3/23/21). "Press Release: Dunad Therapeutics Emerges to Develop Next-generation Small Molecule Therapeutics Based on First Tuneable Targeted Protein Degradation Technology". Cambridge.
Record changed: 2021-11-04


Picture [iito] No Content Marketing 650x100px

More documents for Dunad Therapeutics Ltd.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture [iito] [LSE] Business Portal 650x300px

» top